ESTRO 2024 - Abstract Book

S1512

Clinical - Lower GI

ESTRO 2024

This is the first prospective trial to evaluate high-dose reirradiation for anal cancer recurrences. The initial results are encouraging, but long term follow up is needed to evaluate oncological outcomes and monitor late toxicity. Based on these feasibility data, inclusion into the trial will continue.

Keywords: Anal cancer, reirradiation, proton therapy,

1454

Digital Poster

Treatment of rectal cancer in elderly patients >80 years might not be limited by their age

Eugènia Otero Pla 1 , Andrea Jiménez García 2 , Lucía Ramírez López 2 , Joan Carles Julià Sanahuja 1 , Saba Rabi 1 , Gemma Calvet Molinas 1 , Scarlet Marie Crespo Pérez 1 , David Paez López-Bravo 3 , Anna Cristina Virgili Manrique 3 , Berta Martín Cullell 3 , Jesús Bollo Rodríguez 4 , Maria Carmen Martínez Sánchez 1 , Gemma Sancho Pardo 1 , Josep Balart Serra 1 1 Hospital Santa Creu i Sant Pau, Radiation Oncology, Barcelona, Spain. 2 Hospital Santa Creu i Sant Pau, Colorectal Nursing Unit, Barcelona, Spain. 3 Hospital Santa Creu i Sant Pau, Medical Oncology, Barcelona, Spain. 4 Hospital Santa Creu i Sant Pau, General and Digestive Surgery, Barcelona, Spain

Purpose/Objective:

To evaluate whether the overall survival (OS) of the elderly patients treated for rectal cancer (RC) in the Hospital Santa Creu i Sant Pau, Barcelona, differs from that it would be expected.

Material/Methods:

Patients aged > 80 years treated for RC between 2017 and 2022 were selected from our hospital database. The Barthel Index and CIRS-G calculator were used to classify the fitness of the patients. Treatment sided effects were recorded in all the patients according to RTOG toxicity criteria. Statistical analysis was performed with SPSS software. The OS was calculated by Kaplan-Meier actuarial method taking time from first treatment. Results are expressed as mean ± standard error or percentage.

Results:

We included 69 patients (male n=37; female n=32), mean age 84 years (range: 80-95), with a median follow-up of 24.21 months (range: 1.5-72.6). Of these patients, 23.2% had their cancer between 10 to 15 cm from anal verge, and 55.1% were classified as III stage. Treatments for III stage were: surgery alone (n=6); chemo-radiotherapy (LCRT; n=14) or short-course radiotherapy (SCRT; n=12) followed by surgery, and definitive treatment with LCRT (n=2) or SCRT (n=4). The Barthel index and CIRS-G were > 90 in 68.4% and 3 points in 36.8% patients, respectively. The OS at 5 years for all cohort and particularly for III stage (n= 38), regardless on the type of treatment was 49% (mean 47.3 ± 3.9 months); and 52.2% (mean 48.2 ± 5.2 months), respectively. Any sort of grade 3 was 13% acute and 11.6% late toxicity. There were 35% (n=24) of patients who died during follow-up. However, in 46% of cases the causes of death were not related to RC or treatment complications.